Part 6/8:
In the healthcare sector, Wood discussed the immense potential of multiomics, which encompasses studying various biological components such as DNA, RNA, and proteins. The synergy of sequencing technologies, AI, and gene editing (like CRISPR) is expected to revolutionize drug development, making it faster and less prone to failure. The emergence of cures for chronic diseases may shift the traditional pharmaceutical business model from one relying on ongoing treatment towards more lucrative one-time cures.
Wood posited that these breakthroughs could enhance the return on research and development investment from previously low single-digit rates to anywhere between 15% and 45%.